Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187309 | 0.78 | ALDH1A1 (0.39) | TDP1NPC1ALDH1A1RAB9ATLR8 | |
| SCHEMBL31716073 | 0.78 | KDM4E (0.46) | POLBKMT2AL3MBTL1ALDH1A1CLK1 | |
| SCHEMBL30207735 | 0.77 | CYP1A2 (0.41) | NNMTSIRT2SIRT1POLBTDP1 | |
| SCHEMBL2969903 | 0.77 | CYP1A2 (0.41) | NNMTSIRT2SIRT1POLBTDP1 | |
| SCHEMBL126903 | 0.77 | NNMT (0.41) | NNMTSIRT2SIRT1POLBTDP1 | |
| SCHEMBL29424844 | 0.77 | NNMT (0.41) | NNMTSIRT2SIRT1POLBTDP1 | |
| SCHEMBL4710517 | 0.76 | HSD17B10 (0.33) | NNMTPOLBCYP1A2KMT2ACLK2 | |
| Hydrochloric Acid SCHEMBL3736737 | 0.76 | NNMT (0.40) | NNMTSIRT2SIRT1POLBTDP1 | |
| SCHEMBL30884721 | 0.76 | TLR8 (0.46) | NNMTSIRT2SIRT1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL30078498 | 0.76 | NNMT (0.40) | NNMTSIRT2SIRT1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| CN-115867548-B | RIP1K inhibitors | 里格尔药品股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227469-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2010069322-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2010-06-24 | — | — | WO | disclosed |
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2168959-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-2168960-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-1436292-B1 | 5-METHOXY-8-ARYL-¬1,2,4|TRIAZOLO¬1,5-A|PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2006-08-30 | — | — | EP | disclosed |
| EP-1436292-A1 | 5-METHOXY-8-ARYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6693116-B2 | 8-PHENYL-(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030134873-A1 | Adenosine receptor ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | disclosed |
| WO-2003031445-A1 | 5-METHOXY-8-ARYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031445-A1 | 5-METHOXY-8-ARYL-[1,2,4] TRIAZOLO [1,5-A] PYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NNMT 821/4885SIRT2 326/4885SIRT1 107/4885 |
| US-20100130738-A1 | PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE3B, PDE2A | NNMT 3038/4885SIRT2 1187/4885SIRT1 684/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | NNMT 2034/4885SIRT2 2865/4885SIRT1 1279/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | NNMT 2879/4885SIRT2 1082/4885SIRT1 872/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | NNMT 1168/4885SIRT2 1362/4885SIRT1 1804/4885 |
| US-20030134873-A1 | Adenosine receptor ligands | ADORA1, ADORA2A, ADORA3 | NNMT 2406/4885SIRT2 3370/4885SIRT1 3315/4885 |
| US-20230227469-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | NNMT 2034/4885SIRT2 2865/4885SIRT1 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.